The Technical Analyst
Select Language :
Ikonisys S.A. [ALIKO.PA]

Exchange: EURONEXT Sector: Healthcare Industry: Medical Devices

Ikonisys S.A. Price, Forecast, Insider, Ratings, Fundamentals & Signals

Ikonisys S.A. is listed at the  Exchange

2.78% €1.480

America/New_York / 17 mai 2024 @ 03:41


FUNDAMENTALS
MarketCap: 15.47 mill
EPS: -0.250
P/E: -5.92
Earnings Date: Oct 31, 2023
SharesOutstanding: 10.45 mill
Avg Daily Volume: 0.0077 mill
RATING 2024-05-17
B-
Sell
RATINGS
Rating CashFlow: Neutral
Return On Equity: Sell
Return On Asset: Sell
DE: Neutral
P/E: Sell
Price To Book: Sell
QUARTER GROWTHS
4/212/223/224/221/232/23
Revenuen/an/a
Gr.Profitn/an/a
Ebitn/an/a
Asset n/an/an/an/a
Debtn/an/an/a
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -5.92 | sector: PE 17.08
PE RATIO: COMPANY / INDUSTRY
-0.10x
Company: PE -5.92 | industry: PE 60.12
DISCOUNTED CASH FLOW VALUE
N/A
N/A
Expected Trading Range (DAY)

€ 1.445 - 1.515

( +/- 2.36%)
ATR Model: 14 days

Live Trading Signals (every 1 min)

Forecast 1: 09:51 - €1.469
Forecast 2: 10:41 - €1.466
Forecast 3: 11:21 - €1.466
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
Volume Signals
Price €1.480 (2.78% )
Volume 0.0010 mill
Avg. Vol. 0.0077 mill
% of Avg. Vol 13.55 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Ikonisys S.A.

Last 12 Months

Last 12 months chart data with high, low, open and close for Ikonisys S.A.

RSI

Last 10 Buy & Sell Signals For ALIKO.PA

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            Ikonisys S.A.

ALIKO.PA

Ikonisys S.A., a cell based diagnostics company, engages in the design, manufacturing, marketing, and sale of medical diagnostic products for various cancers in the United States and Europe. It offers Ikoniscope Robotic Microscope that provides automated slide handling, slide scanning, and real-time image capture and analysis, and eliminates various factors that cause human error in testing; oncoFISH bladder that allows scanning and analysis of cells recovered from a voided urine sample; oncoFISH her2, a microscopy application for the determination of the HER2 status of tissue sections from breast tissue biopsies; and oncoFISH anaplastic lymphoma kinase (ALK), a microscopy application for the FISH based detection of rearrangements of the gene encoding anaplastic lymphoma kinase (ALK). The company also provides oncoFISH PTEN, a microscopy application for the FISH based detection of deletions of the PTEN gene is prostate tissue biopsies; circulating tumor cells for characterization of individual tumor cells and ctDNA for global tumor genotype information; Ikonisoft explorer CS, a FISH scanning application for analysis of cell suspension deposited on a slide that has been hybridized with desired combination of FISH probes; Ikonisoft explorer tissue, a FISH scanning application for analysis of various tissue section hybridized with desired combination of FISH probes; and IkoniWAN Gateway, a validated remote access solution for Ikoniscope digital microscopy systems. Ikonisys S.A. is based in Paris, France.

Last 10 Buy Signals

Date Signal @
SETHUSDMay 19 - 19:433 037.22
TKXUSDMay 19 - 19:5012.85
NXMUSDMay 19 - 19:5067.54
TOMOUSDMay 19 - 19:52$0.455
BSVUSDMay 19 - 19:51$64.80
SAKAIUSDMay 19 - 19:485.37
KASUSDMay 19 - 19:470.122
SNBNBUSDMay 19 - 19:43583.68
TONUSDMay 19 - 19:436.26
SCNSOLUSDMay 19 - 19:45204.33

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.